![]() |
| Image Credit: Copilot AI |
Just weeks after news of a sharp national spike in asthma deaths – with South Australia recording the highest increase in a single year (88%) – scientists have revealed a promising new treatment for the chronic lung disease.
Australian researchers have found that a family of proinflammatory molecules called beta common cytokines control inflammation and scarring of the airways (fibrosis) in severe and steroid-resistant asthma.
They believe that a human therapeutic antibody called trabikihart could be the key to effectively blocking inflammation and scarring.
The findings, published in the Journal of Allergy and Clinical Immunology, are a result of a joint study led by researchers from the University of South Australia (UniSA) and the Royal Melbourne Institute of Technology (RMIT), in collaboration with researchers from CSL and SA Pathology.
Joint study leader Dr Damon Tumes, Head of the Allergy and Cancer Immunology Laboratory in the Centre for Cancer Biology*, says the findings are significant.






.jpg)

.jpg)
.jpg)